The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its legacy within the broader industry now presents questions about long-term returns . Alternative versions are undercutting market share, prompting anxieties that supporting companies heavily reliant to Viagra's previous position could be a problema